Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lumicitabine in hospitalized infants with RSV
NCT03333317Phase 2Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2017
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of lumicitabine in respiratory syncytial virus infection (RSV), sponsored by Janssen Pharmaceutical. Started Nov 2017; status: terminated.
02
Drugs
lumicitabine
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT03333317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03333317.